SCHEMBL5619637

SCHEMBL5619637

Cc1cn2cc(Cl)cc(OCc3ccccc3)c2n1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCK P35557 1/20 0.46
ATP4A P20648 2/20 0.44
ATP4B P51164 2/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
STAT3 P40763 1/20 0.44
MAPT P10636 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
BRD4 O60885 2/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PLAU P00749 1/20 0.41
PTGER1 P34995 4/20 0.41
RHEB Q15382 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
P2RX7 Q99572 1/20 0.40
MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9096650 0.99 GCK (0.45) GCKATP4AATP4BHTTSMN1; SMN2
SCHEMBL5423755 0.84 GCK (0.46) GCKATP4AATP4BHTTSMN1; SMN2
SCHEMBL2189993 0.80 ATP4A (0.60) ATP4AATP4BHTTSMN1; SMN2STAT3
SCHEMBL21636964 0.79 HTT (0.44) GCKATP4AATP4BHTTSMN1; SMN2
SCHEMBL5425817 0.77 BRD4 (0.51) ATP4AATP4BHTTSMN1; SMN2STAT3
SCHEMBL31309505 0.77 GRM5 (0.53) SMN1; SMN2MAPTL3MBTL1MAPK1TDP1
SCHEMBL25151340 0.77 STAT3 (0.47) GCKATP4AATP4BHTTSMN1; SMN2
SCHEMBL2194287 0.76 PPARG (0.50) ATP4AATP4BHTTSMN1; SMN2MAPT
SCHEMBL24169608 0.76 RHEB (0.46) GCKHTTSMN1; SMN2STAT3MAPT
SCHEMBL9746834 0.76 PPARG (0.50) ATP4AATP4BMAPTHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189736-B2 Prodrugs of imidazopyridine derivatives ALTANA PHARMA AG (DE) 2007-03-13 US disclosed
US-7141567-B2 Polysubstituted imidazopyridines as gastric secretion inhibitors ALTANA PHARMA AG (DE) 2006-11-28 US disclosed
EP-1313739-B1 ALKYLATED IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2006-07-05 EP disclosed
EP-1286993-B1 IMIDAZOPYRIDIN-8-ONES ALTANA PHARMA AG (DE) 2006-06-07 EP disclosed
EP-1313740-B1 PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2005-11-30 EP disclosed
US-6916825-B2 Alkylated imidazopyridine derivatives ALTANA PHARMA AG (DE) 2005-07-12 US disclosed
US-6869949-B2 Polysubstituted imidazopyridines as gastric secretion inhibitors ALTANA PHARMA AG (DE) 2005-03-22 US disclosed
US-20040214852-A1 Polysubstituted imidazopyridines ALTANA PHARMA AG (DE) 2004-10-28 US disclosed
US-20040198764-A1 Prodrugs of imidazopyridine derivatives SENN-BILFINGER JORG (DE) 2004-10-07 US disclosed
US-20040106642-A1 POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2004-06-03 US disclosed
EP-1286993-A1 IMIDAZOPYRIDIN-8-ONES ALTANA Pharma AG (DE) 2003-03-05 EP disclosed
WO-2002034749-A1 POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2002-05-02 WO disclosed
WO-2001072754-A1 ALKYLATED IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072748-A1 IMIDAZOPYRIDIN-8-ONES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
WO-2001072756-A1 PRODRUGS OF IMIDAZOPYRIDINE DERIVATIVES ALTANA PHARMA AG (DE) 2001-10-04 WO disclosed
EP-0299470-B1 Imidazo[1,2-a]pyridines BYK GULDEN LOMBERG CHEM FAB (DE) 1996-12-04 EP disclosed
US-5112834-A Antisecretory and antiulcer BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1992-05-12 US disclosed
EP-0370056-A1 NEW DIAZOLS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1990-05-30 EP disclosed
WO-1989000570-A1 NEW DIAZOLS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1989-01-26 WO disclosed
EP-0299470-A1 Imidazo[1,2-a]pyridines Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1989-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106642-A1 POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS GIPR, SLC10A2, VIP GCK 197/4885ATP4A 82/4885ATP4B 162/4885
US-20040198764-A1 Prodrugs of imidazopyridine derivatives SI, CYP2E1, UGT1A1 GCK 472/4885ATP4A 518/4885ATP4B 1271/4885
US-20040214852-A1 Polysubstituted imidazopyridines GIPR, VIP, SLC10A2 GCK 310/4885ATP4A 89/4885ATP4B 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.